新型冠状病毒肺炎发病机制及临床研究进展  

Advance in clinical study on pathogenesis on COVID-19

作　　者：闵瑞 刘洁[1] 代喆[1] 孙家忠[1] 邓浩华[1] 李新[1] 吴玉文[1] 黄芪 孙力[1] 杨杪[1] 徐焱成[1] MIN Rui;LIU Jie;DAI Zhe;SUN Jia-zhong;DENG Hao-hua;LI Xin;WU Yu-wen;HUANG Qi;SUN Li;YANG Miao;XU Yan-cheng(Zhongnan Hospital of Wuhan University,Hubei 430071,China)

机构地区：[1]武汉大学中南医院内分泌科,湖北武汉430071

出　　处：《中华医院感染学杂志》2020年第8期1171-1176,共6页Chinese Journal of Nosocomiology

摘　　要：新型冠状病毒肺炎(Corona virus disease 2019,COVID-19)是由一种新的β冠状病毒-新型冠状病毒(2019 novel coronavirus,2019-nCoV)引起,以血管紧张素转化酶2(Angiotensin converting enzyme 2,ACE2)作为受体侵入细胞导致肺损伤,病情加重与继发引起的全身性炎症反应密切相关,重症患者会出现急性呼吸窘迫综合征(Acute respiratory distress syndrome,ARDS)和感染性休克,最终出现多器官功能衰竭。目前大多数药物如巴利替尼、瑞德西韦、氯喹等尚处于临床试验阶段,尚无特效药治疗。COVID-19传染性强,可引起多种严重的并发症,对全球公共安全造成了极大威胁。研究其病原学及发病机制,进而开展对治疗药物和疫苗的临床研究,对及时控制病毒传播,防止病情恶化进展,减少并发症及病死率具有重大意义。The Corona Virus Disease 2019(COVID-19) is caused by a new beta coronavirus-the 2019 novel coronavirus(2019-nCoV). As a receptor, the angiotensin converting enzyme 2(ACE2) invades cells, which results in lung damage. The aggravation of the disease is closely related to the secondary systemic inflammatory response. Critically ill patients may develop to acute respiratory distress syndrome(ARDS) and septic shock, eventually the multiple organ failure. At present, most of the drugs such as balitinib, remdesivir and chloroquine are still in the clinical trial stage, and there is no specific drug for treatment. The COVID-19 is highly infectious and can cause many severe complications, which poses a great threat to global public safety. It is of great significance to study its etiology and pathogenesis and then carry out clinical studies on therapeutic drugs and vaccines so as to control the spread of the virus in time, prevent the deterioration and progression of illness condition, and reduce complications and mortality.

关 键 词：新型冠状病毒肺炎 新型冠状病毒 冠状病毒 

分 类 号：R563.1[医药卫生—呼吸系统]